Market Whales and Their Recent Bets on AMGN Options
Market Whales and Their Recent Bets on AMGN Options
Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
有實力的投資者對Amgen (納斯達克：AMGN) 採取了看漲的策略，這是市場玩家不應忽視的。我們在Benzinga跟蹤公開期權記錄的過程中發現了這一重大舉措。這些投資者的身份尚不清楚，但AMGN的如此大規模舉動通常意味着即將發生一些大事。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我們從今天的觀察中獲得了這些信息，當Benzinga的期權掃描器突出顯示Amgen的12次非凡期權交易時。這種活動水平不同尋常。
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $131,892, and 9 are calls, amounting to $509,076.
這些大戶投資者中總體情緒分化，有58%傾向於看漲，33%傾向於看淡。在這些值得注意的期權當中，有3單看跌期權，總金額爲$131,892，還有9單看漲期權，總金額爲$509,076。
What's The Price Target?
目標價是多少？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $270.0 and $400.0 for Amgen, spanning the last three months.
在評估成交量和未平倉合約後，很明顯，主要市場巨頭正在關注AMGN的價格區間，該區間跨足過去三個月，價格區間爲$270.0至$400.0。
Volume & Open Interest Development
成交量和持倉量的評估是期權交易中的一個關鍵步驟。這些指標揭示了阿里巴巴集團（Alibaba Gr Hldgs）特定執行價格期權的流動性和投資者興趣。下面的數據可視化了在過去30天內，阿里巴巴集團（Alibaba Gr Hldgs）在執行價格在74.0美元到120.0美元區間內的看漲看跌期權中，成交量和持倉量的波動情況。
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 710.62 with a total volume of 2,420.00.
就流動性和興趣而言，今天Amgen期權交易的平均未平倉合約爲710.62，總量爲2,420.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $270.0 to $400.0 over the last 30 days.
在下面的圖表中，我們能夠跟蹤Amgen大宗交易的看漲和看跌期權的成交量和未平倉合約的發展趨勢，在$270.0至$400.0的執行價區間內跨足了過去30天。
Amgen 30-Day Option Volume & Interest Snapshot
安進30天期權成交量和持倉量快照
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 01/16/26 | $37.0 | $35.35 | $37.0 | $370.00 | $136.9K | 63 | 37 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $85.0 | $81.5 | $83.81 | $270.00 | $83.8K | 706 | 10 |
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $9.1 | $7.9 | $9.15 | $325.00 | $64.7K | 556 | 71 |
| AMGN | CALL | SWEEP | BEARISH | 08/02/24 | $6.25 | $6.0 | $6.0 | $345.00 | $63.6K | 556 | 338 |
| AMGN | CALL | TRADE | BEARISH | 12/20/24 | $11.9 | $9.85 | $10.0 | $400.00 | $50.0K | 66 | 0 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | SWEEP | 看好 | 01/16/26 | $37.0 | $35.35 | $37.0 | $370.00 | $136.9千美元 | 63 | 37 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $85.0 | $81.5 | $83.81 | $270.00 | $83.8千美元 | 706 | 10 |
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $9.1 | $7.9 | 9.15美元 | $325.00 | $64.7K | 556 | 71 |
| AMGN | 看漲 | SWEEP | 看淡 | 08/02/24 | 6.25美元 | $6.0 | $6.0 | $345.00 | $63.6K | 556 | 338 |
| AMGN | 看漲 | 交易 | 看淡 | 12/20/24 | $11.9 | $9.85 | $10.0 | $400.00 | $50.0K | 66 | 0 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
在對Amgen周邊的期權交易進行全面審查之後，我們開始更仔細地審視該公司。這包括對其當前市場狀況和表現的評估。
Amgen's Current Market Status
Amgen的當前市場狀況
- With a volume of 618,337, the price of AMGN is up 0.12% at $336.0.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 12 days.
- 在成交量爲618,337的情況下，AMGN的價格爲336.0美元，上漲了0.12%。
- RSI因子暗示底層股票可能被超買。
- 下一次公佈的收益預計將在12天后發行。
Expert Opinions on Amgen
安進的專家意見
In the last month, 2 experts released ratings on this stock with an average target price of $321.5.
在過去一個月中，有2位專家對這隻股票進行了評級，平均目標價爲321.5美元。
- Consistent in their evaluation, an analyst from Argus Research keeps a Buy rating on Amgen with a target price of $340.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Amgen with a target price of $303.
- 在他們的評估中保持一致的是，Argus Research的一位分析師對Amgen保持買入評級，目標價爲340美元。
- 在他們的評估中保持一致的是，摩根士丹利的一名分析師對Amgen保持平權評級，目標價爲303美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多個因子和密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒了解最新的安進期權交易。
譯文內容由第三人軟體翻譯。